Article
Tucatinib Triplet Takes Up Residence in Third-Line Metastatic HER2+ Breast Cancer
Rating:
0.0
Views:
87
Likes:
1
Library:
1
Elisavet Paplomata, MD, discusses the lack of standard third-line regimens for patients with metastatic HER2-positive breast cancer, especially for those with brain metastases.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value